Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that the restless legs syndrome drug market will exceed $1 billion in 2015 up from $200 million in 2005.
According to the new Pharmacor report entitled Restless Legs Syndrome, the market will be driven by increases in the diagnosed population and the launch of three new drugs from Schwarz, XenoPort, and Serono. Each of the three new agents will launch successfully for restless legs syndrome on the strength of product differentiation: Schwarz's rotigotine CDS (Neupro) will boast a transdermal formulation; XenoPort's XP-13512 will possess improved pharmacokinetics; and Serono's safinamide will offer new mechanisms of action.
"The approval of Schwarz's rotigotine CDS, and XenoPort's XP-13512 will drive a four-fold increase in the drug-treated population and a six-fold increase in total market sales by 2015," said Julie Kerner, Ph.D., analyst at Decision Resources. "The most successful emerging agent in the restless legs syndrome market will be rotigotine CDS, sales for which will account for 46% of the total restless legs syndrome market growth by 2015."
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies that assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development.
About Decision Resources
Decision Resources (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
Web site: http://www.decisionresources.com/